Ranibizumab for the treatment of neovascular age-related macular degeneration: A review

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 1850-1861

  Kourlas, Helen ^a,b   Abrams, Paris ^b  

^a LONG ISLAND UNIVERSITY   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

age related macular degeneration; ARMD; choroidal neovascularization; ranibizumab

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; RANIBIZUMAB;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENDOPHTHALMITIS; EYE INFLAMMATION; HUMAN; INTRAOCULAR HYPERTENSION; LIFE EXPECTANCY; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION;

AGING; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 36749080289     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.008     Document Type: Article

References (24)

1. Zarbin M. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122 (2004) 598-614
2. Pauleikhoff D. Neovascular age-related macular degeneration: Natural history and treatment outcomes. Retina 25 (2005) 1065-1084
3. Bourla D., and Young T. Age-related macular degeneration: A practical approach to a challenging disease. J Am Geriatr Soc 54 (2006) 1130-1135
4. deJong P. Age-related macular degeneration. N Engl J Med 355 (2006) 1474-1485
5. Age-related macular degeneration. National Eye Institute Web site. Available at:. http://www.nei.nih.gov/health/maculardegen/armd_facts.asp#1a Accessed May 15, 2007
6. Nowak J. Age-related macular degeneration (AMD): Pathogenesis and therapy. Pharmacol Rep 58 (2006) 353-363
7. Arroyo J. Age-related macular degeneration. UpToDate Online version 15.1. Available at:. http://www.uptodateonline.com/utd/content/topic.do?topicKey=priophth/469 0&type=A&selectedTitle=l-8 Accessed May 15, 2007
8. Ng E., and Adamis A. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. CanJ Ophthalmol 40 (2005) 352-368
9. Clemons T., Milton R., Klein R., et al., Age-Related Eye Disease Study Research Group. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS report no. 19. Ophthalmology 112 (2005) 533-539
10. Fine S., Berger J., Maguire M., and Ho A. Age-related macular degeneration. N Engl J Med. 342 (2000) 483-492
11. Ferris III F., Kassoff A., Bresnick G., and Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol. 94 (1982) 91-96
12. Dugel P. Treatments for age-related macular degeneration. Manag Care 15 Suppl 7 (2006) 7-15
13. Rothen M., Jablon E., Monares G., et al. Anti-macular degeneration agents. Ophthalmol Clin North Am 18 (2005) 561-567
14. Macugen [package insert] (2006), Pfizer Inc, New York, NY
15. Lucentis [package insert] (2006), Genentech Inc, San Francisco, Calif.
16. van Wijngaarden P., Coster D., and Williams K. Inhibitors of ocular neovascularization: Promises and potential problems. JAMA 293 (2005) 1509-1513
17. Rosenfeld P., Brown D., Heier J., et al., MARINA Study Group. Ranibizumab For neovascular age-related macular degeneration. N Engl J Med. 355 (2006) 1419-1431
18. Heier J., Antoszyk A., Pavan P., et al. Ranibizumab for treatment of neovascular age-related macular degeneration: A phase I/II multicenter, controlled, multidose study. Ophthalmology 113 (2006) 642
19. Krzystolik M., Afshari M., Adamis A., et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120 (2002) 338-346
20. Heier J., Boyer D., Ciulla T., et al., FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. [published correction appears in Arch Ophthalmol. 2007;125:138]. Arch Ophthalmol. 124 (2006) 1532-1542
21. Brown D., Kaiser P., Michels M., et al., ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 355 (2006) 1432-1444
22. Steinbrook R. The price of sight-ranibizumab, bevacizumab and the treatment of macular degeneration. N Engl J Med 355 (2006) 1409-1412
23. Ranibizumab. In: Fleming T. (Ed). 2007 Drug Topics Redbook (2007), Thompson Healthcare, Montvale, NJ 475
24. Kourlas H., and Schiller D. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A review. Clin Ther 28 (2006) 36-44